Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Incyte

Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?

Analysts expect nearly 450% EPS growth in 2025, making execution on its core portfolio critical for sustaining the outperformance experienced so far YTD.

MarketBeat

Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink?

Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Stocks Flashing Renewed Technical Strength: Incyte

Incyte sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Incyte Joins Rank Of Stocks With 95-Plus Composite Rating

Incyte saw its IBD SmartSelect Composite Rating jump to 98 Wednesday, up from 90 the day before.

Investors Business Daily

Incyte Sees IBD RS Rating Improve To 79

A Relative Strength Rating upgrade for Incyte shows improving technical performance. Will it continue?

Investors Business Daily

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Incyte Corporation (NASDAQ:INCY) reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.

Benzinga

Incyte’s Q2 2025 Earnings: What to Expect

Incyte is gearing up to report its fiscal second-quarter earnings later this month, with analysts forecasting a sharp surge in profitability, projecting triple-digit year-over-year profit growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Incyte Stock Gets Relative Strength Rating Lift

A Relative Strength Rating upgrade for Incyte shows improving technical performance. Will it continue?

Investors Business Daily

Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?

Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.

Investors Business Daily

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

Incyte has underperformed relative to its biotech peers over the past year, though Wall Street analysts maintain a cautiously optimistic view on the stock’s outlook.

Barchart

Is Wall Street Bullish or Bearish on Incyte Stock?

Despite Incyte’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Incyte Earnings Preview: What to Expect

Incyte is all set to release its fiscal first-quarter earnings later this month, and analysts project a high double-digit profit growth.

Barchart

Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.

Investors Business Daily

Incyte Scores Relative Strength Rating Upgrade; Hits Key Threshold

Incyte sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Incyte Earns Relative Strength Rating Upgrade; Hits Key Benchmark

Incyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82.

Barchart

Are Wall Street Analysts Bullish on Incyte Stock?

Incyte has continued to observe strong demand for Jakafi and Opzelura, leading to robust growth in sales, and analysts remain bullish on the stock’s prospects.

Investors Business Daily

Incyte Stock Sees Relative Strength Rating Rise To 71

Incyte shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Barchart

What You Need to Know Ahead of Incyte's Earnings Release

Biopharma major Incyte is expected to announce its fourth-quarter results later this month and analysts expect a significant double-digit growth in earnings.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Incyte Meets 80-Plus Relative Strength Rating Benchmark

Incyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.

Barchart

Is Incyte Stock Outperforming the Dow?

Incyte has outperformed the Dow recently, and analysts remain moderately optimistic about the stock’s prospects.

Investors Business Daily

Stocks With Rising Relative Price Strength: Incyte

Incyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 81.

Investors Business Daily

Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review

The stock market tested key levels but ultimately rallied, with many leaders flashing buy signals. Bitcoin raced toward $100,000.

Investors Business Daily

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.

Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.

Investors Business Daily

Stocks Flashing Renewed Technical Strength: Incyte

Incyte sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges

Incyte stock broke out Tuesday after sales of the company's two key products beat analysts' third-quarter projections.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.